Apanay D C, Neylan J F, Ragab M S, Sgoutas D S
Department of Pathology, Emory University Hospital, Atlanta, Georgia 30322.
Transplantation. 1994 Sep 27;58(6):663-9.
Blood specimens from twenty-six renal transplant recipients treated with cyclosporine (CsA) were collected at weekly intervals, two months after transplantation. Specimens were grouped according to their CsA concentrations. Group I consisted of ten specimens with CsA concentration of >400 ng/ml; group II consisted of ten specimens with CsA concentrations ranging from 120-300 ng/ml; and group III consisted of six specimens with CsA concentrations of < 100 ng/ml. In addition, specimens from five renal transplant patients who, instead of CsA, received the immunosuppressant FK506 (group IV), and from six healty individuals were included. Plasma low-density lipoproteins (LDL) were isolated and their susceptibility to oxidation was studied by continuously monitoring the formation of conjugated dienes during copper ion-mediated oxidation. Patients with higher blood concentrations of CsA (groups I and II) had significantly higher oxidizability of LDL, as indicated by the shorter time required to start the oxidation (lag phase). The oxidizability of samples with low concentration of CsA (group III) was not significantly different from that of FK506-treated patients or healthy individuals. There was a negative correlation (r = -0702, P < 0.01) between oxidizability (lag phase) and CsA concentration in LDL. No correlation between blood CsA and plasma cholesterol or triglyceride concentration was evident during a three-month period postoperatively. Similarly, no correlation between the degree of oxidizability and plasma cholesterol or triglycerides was found at the time of the experiment. These findings suggest a prooxidant effect of CsA to plasma LDL, and may indicate that CsA is an important risk factor in the accelerated atherosclerosis of renal transplant recipients.
在肾移植术后两个月,每周采集26名接受环孢素(CsA)治疗的肾移植受者的血液样本。样本根据其CsA浓度分组。第一组由10个CsA浓度>400 ng/ml的样本组成;第二组由10个CsA浓度在120 - 300 ng/ml之间的样本组成;第三组由6个CsA浓度<100 ng/ml的样本组成。此外,还纳入了5名接受免疫抑制剂FK506(第四组)而非CsA治疗的肾移植患者以及6名健康个体的样本。分离血浆低密度脂蛋白(LDL),通过连续监测铜离子介导氧化过程中共轭二烯的形成来研究其氧化易感性。CsA血药浓度较高的患者(第一组和第二组)的LDL氧化能力显著更高,表现为开始氧化所需时间(滞后期)更短。低浓度CsA样本(第三组)的氧化能力与接受FK506治疗的患者或健康个体的氧化能力无显著差异。氧化能力(滞后期)与LDL中CsA浓度之间呈负相关(r = -0.702,P < 0.01)。术后三个月期间,血液中的CsA与血浆胆固醇或甘油三酯浓度之间无明显相关性。同样,在实验时,氧化程度与血浆胆固醇或甘油三酯之间也未发现相关性。这些发现表明CsA对血浆LDL有促氧化作用,可能表明CsA是肾移植受者动脉粥样硬化加速的一个重要危险因素。